SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 4 analyzed stories

Kiniksa Pharmaceuticals 3Q 2026: Revenue $285.97M, Net income $47.35M, EPS $0.56— 10-Q Summary

Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $285.97 million, up 58.1% from a year earlier. Net income rose to $47.35 million and diluted earnings per share, which means profit per share, reached $0.56, helped mainly by more patients receiving ARCALYST.

Published:

Updated:

What happened

Kiniksa Pharmaceuticals reported third-quarter 2026 revenue of $285.97 million, up 58.1% from a year earlier, and net income of $47.35 million, or $0.56 per share, mainly from more patients receiving ARCALYST. The company also said it expects ARCALYST net product revenue of $1.045 billion to $1.05 billion in 2026.

Global impact / market context

The report shows the company earned a profit and grew sales quickly. For ordinary investors, that means the business is selling more of its main product and keeping money after costs. The 2026 revenue outlook gives a rough idea of what the company expects next, but it is a company estimate, not a guarantee.

What to watch

  1. The exact ARCALYST revenue figure for the quarter, because the facts give total revenue but not the product-only amount for the period. This shows how much of sales comes from the main product.
  2. Operating expenses of $231.734 million next to product revenue, because costs near sales levels affect how much profit remains. This matters for whether profit can continue.
  3. Whether the 2026 ARCALYST revenue range of $1.045 billion to $1.05 billion is met, because the facts show only the company's expectation, not actual results. This matters for judging follow-through.

Affected assets

  • ARCALYST
  • Kiniksa Pharmaceuticals International plc

Evidence